3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Leukemia, Myelomonocytic, Chronic
2
Anemia, Refractory, with Excess of Blasts
2
Wilms Tumor
1
Uveal Melanoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Primary Malignant Peripheral Nerve Sheath Tumors
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligodendroglioma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Hepatoblastoma
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
GATA2 Deficiency
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Anemia, Refractory
1
Interventions
fludarabine
2
durvalumab
2
Cyclophosphamide
2
ruxolitinib
1
repotrectinib
1
ponatinib
1
pembrolizumab
1
gilteritinib
1
fludarabine phosphate
1
cemiplimab
1
atezolizumab
1
Whole-Body Irradiation
1
Tacrolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Nivolumab
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Immunotherapy
1
Idarubicin
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Cytarabine
1
Cisplatin
1
CPI-0610
1
Busulfan
1
Bone Marrow Transplantation
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Vorinostat
×
90 days
×
Clear all
No trials found.